Effect of galantamine on platelet functions in healthy elderly people
暂无分享,去创建一个
[1] M. Skrzypek,et al. Oral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in elderly people in Poland , 2012, BMC Cardiovascular Disorders.
[2] A. Işık,et al. Trospium and cognition in patients with Late Onset Alzheimer Disease , 2009 .
[3] A. Işık,et al. Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease , 2009, International Psychogeriatrics.
[4] A. Wimo,et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial , 2009, The Lancet Neurology.
[5] B. Everitt,et al. Analyses of mortality risk in patients with dementia treated with galantamine , 2009, Acta neurologica Scandinavica.
[6] B. Winblad,et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment , 2008, Neurology.
[7] Bradley R. Johnson,et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. , 2007, The American journal of psychiatry.
[8] S. Salloway,et al. Galantamine treatment of vascular dementia , 2007, Neurology.
[9] S. López-Pousa,et al. Factores asociados a la mortalidad en pacientes con enfermedad de Alzheimer tratados con galantamina , 2006 .
[10] Qinying Zhao,et al. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers , 2005, Current medical research and opinion.
[11] Mark Crowther,et al. Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.
[12] K. Shulman,et al. Drug‐Induced Lithium Toxicity in the Elderly: A Population‐Based Study , 2004, Journal of the American Geriatrics Society.
[13] T. Erkinjuntti,et al. Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine , 2003, Dementia and Geriatric Cognitive Disorders.
[14] G. Small,et al. Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease , 2003, European journal of neurology.
[15] G. Small,et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. , 2003, Clinical therapeutics.
[16] P. Tariot,et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.
[17] E. Peskind,et al. Galantamine in AD , 2000, Neurology.
[18] J. George,et al. The clinical importance of acquired abnormalities of platelet function. , 1991, The New England journal of medicine.
[19] P. Hamet,et al. Abnormalities of Platelet Function in Hypertension and Diabetes , 1985, Hypertension.
[20] A. Turon Estrada,et al. [Mortality-associated factors in patients with Alzheimer's disease treated with galantamine]. , 2006, Medicina clinica.
[21] Joël Belmin,et al. Prevention of Cardiovascular Events in Elderly People , 2005, Drugs & aging.
[22] A. Kurz,et al. Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers. , 2001, Clinical therapeutics.
[23] J. Morris,et al. Panel discussion:recommendations for prescribers , 2001 .
[24] J. Morris. Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Introduction. , 2001, Clinical therapeutics.